An observational study in Carpal Tunnel Syndrome and Chronic Pain, sponsored by Ahram Canadian University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Ahram Canadian University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 7 observational ones, and was the 8th registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:
Ahram Canadian University · Sites in Egypt
Ages 18–60 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–45 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–60
Ahram Canadian University · Sites in Egypt
Ages 18–60
Ahram Canadian University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 10 started in 2023.
This study's enrollment of 229 is above the median of 92 across 131 observational studies indexed under Carpal Tunnel Syndrome.
Median enrollment 92 across the 3 interventional studies, 50 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study will examine whether sensory testing performed at study entry can help predict the pain pattern present 12 months later in adults with carpal tunnel syndrome (CTS). Adults with clinically and electrodiagnostically confirmed CTS will undergo baseline clinical assessment, questionnaires, nerve-conduction testing, pain-phenotype classification, and quantitative sensory testing (QST). The main QST measures will assess pressure-pain sensitivity at a site away from the affected hand, temporal summation of pain, and conditioned pain modulation. Participants will receive their usual clinical care; the study will not assign treatment. They will be reassessed at 6 and 12 months. The main outcome is whether the participant has a predominantly neuropathic CTS pain phenotype or a mixed neuropathic-nociplastic pain phenotype at 12 months. Follow-up phenotype assessors will not have access to baseline QST results. The study hypothesis is that baseline QST will provide prognostic information beyond standard clinical and electrodiagnostic characteristics.
Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Electrodiagnostic evidence of median neuropathy at the wrist:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with clinical and electrodiagnostic evidence of carpal tunnel syndrome.
Diagnostic Test: Quantitative Sensory Testing (QST)
Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
Progression to Nociplastic Pain
Development of nociplastic pain in patients with carpal tunnel syndrome, as identified by a Kosek, by clinical criteria suggest by E., Clauw, D., Nijs, J., Baron, R., Gilron, I., Harris, R. E., ... \& Sterling, M. (2021). Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain, 162(11), 2629-2634.
Time frame: 1 year from the start of the study
Change in Quantitative Sensory Testing (QST) Measures
A significant change in QST measures could indicate the progression of sensory abnormalities in the participants. QST measures include thermal detection and pain thresholds, mechanical detection and pain thresholds, and vibration detection thresholds. Each of these thresholds is measured using specific testing equipment and protocols, and the exact scoring can vary based on the specific equipment and protocol used. In general, lower thresholds (i.e., the patient detects the stimulus at lower intensities) may indicate heightened sensitivity or hyperalgesia, while higher thresholds may indicate reduced sensitivity or hypoesthesia. Changes in these thresholds over time can indicate a worsening of sensory dysfunction.
Time frame: Changes in QST at baseline and 1 year
Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)
The 11-item BCTQ Symptom Severity Scale is scored from 1 to 5 per item; the scale score is the mean of completed items, with higher values indicating greater CTS symptom severity.
Time frame: Baseline, 6 months and 12 months
Boston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)
The 8-item BCTQ Functional Status Scale assesses difficulty with activities affected by CTS; higher mean scores indicate greater functional limitation
Time frame: Baseline, 6 months, and 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Sep 2026, 37 months.
Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's 37 months is above that.
Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jul 2024 → Sep 2026 and completion Nov 2024 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahram Canadian University